Lineage Cell Therapeutics Inc (LCTX) — Cash Flow Quality Index
Lineage Cell Therapeutics Inc (LCTX) has a Cash Flow Quality Index of -2.76x as of December 2020. Operating cash flow of $-5.64 Million is below net income of $2.04 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Lineage Cell Therapeutics Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Lineage Cell Therapeutics Inc Cash Flow Quality Index (2016–2016)
Historical Cash Flow Quality Index for Lineage Cell Therapeutics Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Lineage Cell Therapeutics Inc (LCTX) cash conversion ratio.
Annual Cash Flow Quality Index for Lineage Cell Therapeutics Inc (2016–2016)
Year-by-year earnings quality comparison for Lineage Cell Therapeutics Inc.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2016 | -2.27x | $-42.33 Million | $18.62 Million | — |